Insightful analysis and commentary for the US and global equity investor
Contributors: Douglas McIntyre Jon C. Ogg

Previous Posts

Friday, July 07, 2006

Stem Cell Measures Appear Delayed


Earlier in the week we alerted that there is a "possibility" that there will be three different stem cell research bills as soon as next week. This is still on the future schedule but no longer appears set on next week's calendar. This was already passed in the House of Representatives for a broader use of federal funds to be granted for embryonic stem cell research (with limitations of course).

Any bill will not be a grant of monies over all sorts of embryonic stem cell research, although you can bet it will stir controversy either way. These grants would be regarding "Donated" frozen embryos from in-vitro fertilization procedures and those materials that are slated to be destroyed at fertility clinics. One other measure would BAN fetus farming and one measure would allocate potential federal funding for stem cell research for stem cells taken from other human material outside of embryos.

Delays often occur in congressional measures, and this may be the case here.

The stocks that have historically had the most exposure to stem cell research backing are the following: Aastrom Bio (ASTM), Geron (GERN), StemCells (STEM), ViaCell (VIAC), Thermogenesis (KOOL) and Advanced Cell Technology Inc. (ACTC-OTC); Invitrogen (IVGN) has also been recently lumped in after a deal with Geron.

Jon C. Ogg
July 7, 2006

Powered by Blogger